Navigation Links
Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke

EXACT and CAPTURE 2 Findings Suggest Improved Outcomes in Carotid Artery Stenting

ABBOTT PARK, Ill., March 26, 2007 /PRNewswire-FirstCall/ -- Positive 30-day results from two Abbott studies confirm that carotid stenting can be performed with positive results by physicians with a variety of background experience in real-world (non-clinical trial) settings in patients who are not favorable candidates for surgery. Interim results from the first 1,500 patients enrolled in EXACT (Emboshield and Xact Post Approval Carotid Stent Trial) and from the first 600 patients enrolled in CAPTURE 2 (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events) were presented today by William A. Gray, M.D., FACC, of Medical Center in New York, in a late-breaking clinical trial session at the 56th Annual of Cardiology Scientific Session in New Orleans.

"The results from these two studies reaffirm that carotid stenting is a safe, effective minimally invasive treatment option for patients with carotid artery disease who may be at risk of experiencing adverse events from surgery," said Dr. Gray. "The results also suggest that patient outcomes are improving over time as the practice of carotid stenting increases."

The primary endpoint of death, stroke and heart attack at 30 days was 4.6 percent in EXACT and 5.2 percent in CAPTURE 2. Further, results from EXACT and CAPTURE 2 demonstrated a low rate of 30-day major stroke and/or death in patients treated with Abbott's carotid stent systems (1.8 percent in EXACT, 1.3 percent in CAPTURE 2). The EXACT post-approval study utilizes Abbott's Xact(R) Rapid Exchange Carotid Stent System and Emboshield BareWire(TM) Rapid Exchange Embolic Protection System. CAPTURE 2 utilizes the company's ACCULINK(TM) Carotid Stent System and ACCUNET(TM) Embolic Protection System.

"The results of our most recent post market studies are very encouraging, and suggest continued progress in improving carotid stenting outcomes," said Chuck Foltz, vice president, Abbott Vascular. "We are proud of our leadership in carotid stenting trials, with more than 10,000 patients enrolled in Abbott trials in the United States. These studies demonstrate that carotid stenting is making a difference in the lives of patients."

New Study Evaluates Next-Generation Embolic Protection Device

Abbott's next-generation Emboshield PRO(TM) Embolic Protection System, currently available in Europe, is under safety and effectiveness evaluation in PROTECT, a new U.S. clinical trial which recently began enrolling patients. The study will include 320 high surgical risk patients at 50 U.S. clinical sites. Patients will be evaluated at 30 days following stent placement to gather safety and efficacy data to support a 510(k) application to the U.S. Food and Drug Administration (FDA) for Emboshield PRO.

About Carotid Artery Disease and Stroke

Stroke is the third leading cause of death in the United States and the number one cause of disability in adults, according to the American Heart Association. Approximately 25 percent of strokes are caused by carotid artery disease. Clogged carotid arteries in the neck can cause ischemic stroke, the most common type. More than 700,000 Americans will have new (500,000) or recurrent (200,000) strokes each year, and more than 150,000 will die.

About Carotid Stenting

Carotid artery stenting is a minimally invasive treatment option for patients who require intervention and who are at high risk for complications from carotid endarterectomy, an invasive surgical procedure. Carotid artery stenting is performed by delivering a stent on a catheter through the femoral artery in the groin. The catheter is maneuvered through the patient's vasculature to the carotid artery. The stent, which is designed to prevent arterial plaque and debris from breaking off and blocking blood flow to the brain, is then expanded at the site of the blockage. The embolic protection filter captures and removes any debris that has become dislodged during the carotid stenting procedure.

Currently, carotid artery stenting in the United States is approved by the FDA for treating patients who are at high risk for experiencing adverse events from surgery. Abbott's carotid stenting devices are also being investigated in a much broader group of patients who are not at high risk for surgery through two randomized clinical trials, CREST and ACT I, which compare stenting to surgery. Results from CREST and ACT I are expected to become available within three years.

Clinical evidence from Abbott's studies supported Abbott's request to the Centers for Medicare and Medicaid Services (CMS) to reconsider its carotid stenting coverage policy. As a result, CMS last month proposed expanding carotid stenting coverage, whereby certain high surgical risk Medicare patients who have a severe carotid blockage and have not yet experienced stroke or a transient ischemic attack would, for the first time, have access to carotid artery stenting.

To date, more than 60,000 patients worldwide have undergone carotid stenting with Abbott's carotid stent systems.

For images of Abbott's carotid stent and embolic protection systems and other information, please visit the company's online ACC newsroom at http://www.abbottvascular.com/ACCpresskit .

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfo lio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com .

CONTACT: Media, Karin Bauer Aranaz, +1-415-859-3414, , Nicole Osmer, +1-650-454-0504, , or Financial, Tina Ventura, +1-847-772-5006, , all of Abbott karin.baueraranaz@av.abbott.com nicole.osmer@av.abbott.com tina.ventura@abbott.com

Web site: http://www.abbott.com/http://www.abbottvascular.com/ACCpresskit/

Ticker Symbol: (NYSE:ABT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):